United States: Supreme Court Interprets BPCIA Disclosure And Notice Provisions

On June 12, 2017, in a unanimous decision, the Supreme Court of the United States decided Sandoz Inc. v. Amgen Inc., which concerned certain disclosure and notice requirements imposed by the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), 42 U.S.C. § 262(l), on applicants seeking FDA approval for biosimilars of biologic drug products. The BPCIA is a "complex statutory scheme" that "establishes processes both for obtaining FDA approval of biosimilars and for resolving patent disputes between manufacturers of licensed biologics and manufacturers of biosimilars." In particular, the Court resolved two issues concerning the BPCIA, holding that (i) an injunction is not an available remedy under federal law to force a biosimilar applicant to provide a copy of its FDA application and information about how the biosimilar is manufactured to the manufacturer of a licensed biologic product prior to the start of a patent infringement case; and (ii) an applicant may give the biologic manufacturer notice of "commercial marketing" of its biosimilar either before or after receiving FDA approval, i.e., licensure, for its product.

Some background may be helpful to understand these issues. In contrast to "traditional" drugs that are chemically synthesized, biologics are drug products derived from natural, biological sources such as animals or microorganisms. Under the BPCIA, manufacturers of biologics may seek FDA marketing approval using two different pathways. One pathway is that the FDA may "license" a new biologic drug if a manufacturer demonstrates, among other things, that the biologic is "safe, pure, and potent." Alternately, the BPCIA provides an abbreviated approval pathway for licensure of a biosimilar by "piggyback[ing] on the showing made by the manufacturer (sponsor) of a previously licensed biologic (reference product)." Under this abbreviated route, an applicant must demonstrate that its proposed biosimilar product is "highly similar" to the reference product and that no "clinically meaningful differences" exist between the products in terms of "safety, purity, and potency." The submission of a biosimilar application to the FDA constitutes an "artificial" act of infringement that can allow a patent infringement lawsuit to be brought before the biosimilar receives FDA approval or the commencement of commercial marketing.

In this case, Amgen markets a biologic called Neupogen® (filgrastism), which is used to stimulate the production of white blood cells. Amgen has marketed Neupogen since 1991, and has patents on methods of using and manufacturing filgrastism. In May 2014, Sandoz filed an application with the FDA seeking approval to market a filgrastism biosimilar to be named Zarxio®. Sandoz's biosimilar application cited Neupogen as the reference product. In July 2014, following the FDA's acceptance of the biosimilar application for review, Sandoz notified Amgen that it had submitted the application and intended to commercially market Zarxio upon receiving FDA approval. Amgen sued Sandoz for patent infringement in October 2014, and also alleged violations of California's unfair competition law. While the case was pending, the FDA licensed Zarxio.

The issues in the Supreme Court's opinion concern the requirements and timing for certain disclosures that a biosimilar applicant makes to the biologic manufacturer. The first question the Court addressed is whether injunctive relief is available to enforce a BPCIA requirement that the biosimilar applicant "shall provide" a copy of its biosimilar application and manufacturing information to the biologic manufacturer. In addition to seeking this injunction under federal law via the BPCIA, Amgen also sought an injunction under California's unfair competition law. The second question addressed by the Court is whether a biosimilar applicant's notice of commercial marketing is effective if it is provided prior to the FDA's decision to license the biosimilar. The BPCIA requires notice to be provided "not later than 180 days before the date of the first commercial marketing" of the biosimilar. Thus, this issue is important because if notice may be provided 180 days or more before FDA approval, commercial marketing may begin immediately after licensure; otherwise, a biosimilar applicant would not be able to market its product until 180 days after approval.

With regard to the first question, the Court considered whether § 262(l)(2)(A)'s requirement that an applicant "shall provide" the sponsor with its biosimilar application and information about how the biosimilar is manufactured "within 20 days" after being informed that the FDA accepted the application for review is enforceable by an injunction under either federal or state law. The Court held that under federal law an injunction is not available to enforce this requirement. The Court reasoned that the BPCIA includes a provision that provides a remedy for when an applicant fails to turn over its application and manufacturing information. This provision, found in § 262(l)(9)(C), allows a sponsor "to bring an immediate declaratory-judgment action for artificial infringement." The Court decided that the existence of this remedy in the BPCIA acts to exclude all other federal remedies, including injunctive relief. In support of this, the Court noted that Congress expressly provided injunctive relief for breaching confidentiality provisions under the BPCIA; thus, if it had intended to do so, Congress could have done the same for the breach of the disclosure requirement. But since Congress did not do so, the Court found that Congress did not intend for sponsors to have access to injunctive relief to enforce the disclosure requirement. Consequently, injunctive relief is not available under federal law to enforce the BPCIA's disclosure requirement.

As to whether injunctive relief may be available under California's unfair competition law, instead of deciding the issue, the Court remanded it to the Federal Circuit with instructions about how to proceed. Previously, the Federal Circuit had concluded that no injunctive relief was available under California's unfair competition law, but the Court found that this conclusion was based on an improper application of the BPCIA's requirements to this question of state law. Thus, on remand, the Court instructed the Federal Circuit to consider "whether California law would treat noncompliance with § 262(l)(2)(A) as 'unlawful.'"

Regarding the second question, the Court considered whether the BPCIA's requirement that an applicant "shall provide notice to the reference product sponsor not later than 180 days before the date of first commercial marketing of the [biosimilar] product licensed under [the BPCIA]" could be satisfied by providing notice prior to the FDA licensing the biosimilar product, or whether such notice is effective only after the biosimilar is licensed. See § 262(l)(8)(A). While the Federal Circuit had determined that an applicant's biosimilar must be "licensed" at the time applicant gives notice, the Supreme Court disagreed. The Court found that the use of the word "licensed" in the statute "merely reflect[ed] the fact that, on the 'date of the first commercial marketing,' the product must be 'licensed.'" Thus, the Court held that notice can be provided before or after the FDA licenses the biosimilar. The Court found that this was supported by the statutory context of § 262(l)(8)(A), because the provision contained a single timing requirement and if Congress intended to have more than one timing requirement it would have done so, as it did in the following subparagraph of this section. Thus, the Court's decision allows a biosimilar applicant to provide notice of commercial marketing to run out the 180 day clock before actually receiving FDA approval to commercially market the biosimilar.

The decisions here are unlikely to be the Supreme Court's last decisions concerning the BPCIA's "complex statutory scheme." The Court is plainly wrestling with the statute, as well as the policy considerations implicated by the statute. When addressing the notice of commercial marketing timing issue, the Court mentioned that there were numerous policy arguments put forth by Amgen, Sandoz, and the Government as Amicus Curiae. Rather than addressing the merits of the policy arguments, however, the Court stated that "[t]he plausibility of the contentions on both sides illustrates why such disputes are appropriately addressed by Congress, not the courts." Furthermore, Justice Breyer wrote a concurring opinion stating that "Congress implicitly delegated to the [FDA] authority to interpret [the] same [statutory] terms. That being so, if that agency, after greater experience administering this statute, determines that a different interpretation would better serve the statute's objectives, it may well have authority to depart from, or to modify, today's interpretation . . ., though we need not now decide any such matter." Thus, it may be some time before interpretations of the BPCIA become settled law.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.